SG11202004806SA - Antibodies to lilrb2 - Google Patents
Antibodies to lilrb2Info
- Publication number
- SG11202004806SA SG11202004806SA SG11202004806SA SG11202004806SA SG11202004806SA SG 11202004806S A SG11202004806S A SG 11202004806SA SG 11202004806S A SG11202004806S A SG 11202004806SA SG 11202004806S A SG11202004806S A SG 11202004806SA SG 11202004806S A SG11202004806S A SG 11202004806SA
- Authority
- SG
- Singapore
- Prior art keywords
- lilrb2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762610050P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/066819 WO2019126514A2 (en) | 2017-12-22 | 2018-12-20 | Antibodies for lilrb2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004806SA true SG11202004806SA (en) | 2020-06-29 |
Family
ID=65041919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004806SA SG11202004806SA (en) | 2017-12-22 | 2018-12-20 | Antibodies to lilrb2 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10723798B2 (he) |
| EP (2) | EP3728318A2 (he) |
| JP (2) | JP7391868B2 (he) |
| KR (1) | KR20200103706A (he) |
| CN (1) | CN111699196A (he) |
| AR (1) | AR114002A1 (he) |
| AU (1) | AU2018389111A1 (he) |
| BR (1) | BR112020012650A2 (he) |
| CA (1) | CA3087166A1 (he) |
| CL (1) | CL2020001637A1 (he) |
| EA (1) | EA202091540A1 (he) |
| IL (1) | IL275268A (he) |
| MX (1) | MX2020006668A (he) |
| SG (1) | SG11202004806SA (he) |
| WO (1) | WO2019126514A2 (he) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| AU2018389111A1 (en) | 2017-12-22 | 2020-06-18 | Jounce Therapeutics, Inc. | Antibodies to LILRB2 |
| EP3762426A2 (en) * | 2018-03-06 | 2021-01-13 | Imcare Biotech, LLC | Serine protease inhibitor kazal (spik) compositions and methods |
| MX2021000009A (es) | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
| US20230235050A1 (en) * | 2019-09-20 | 2023-07-27 | Invectys SAS | Single-domain antibodies directed against lilrb2 |
| WO2021146303A1 (en) * | 2020-01-13 | 2021-07-22 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| IL296714A (he) * | 2020-03-27 | 2022-11-01 | Univ Indiana Trustees | יעדים אימונותרפיוטיים במיאלומה מרובה ושיטות לזיהוי שלהם |
| AU2021265801A1 (en) * | 2020-05-01 | 2022-11-17 | Ngm Biopharmaceuticals, Inc. | ILt-binding agents and methods of use thereof |
| EP3981789A1 (en) * | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
| US20220289847A1 (en) * | 2021-03-09 | 2022-09-15 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
| WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
| CN114805568B (zh) * | 2022-06-28 | 2022-09-02 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN116333128A (zh) * | 2022-06-28 | 2023-06-27 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| WO2024008190A1 (en) * | 2022-07-08 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Anti-lilrb2 antibodies and uses thereof |
| WO2024041315A1 (en) * | 2022-08-22 | 2024-02-29 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-lilrb2 antibodies and uses thereof |
| CN117417454B (zh) * | 2023-12-19 | 2024-03-05 | 北京索莱宝科技有限公司 | 抗鸡IgY抗体及其应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| PT1034298E (pt) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US20040241167A1 (en) | 2001-06-25 | 2004-12-02 | Nicole Suciu-Foca | Ilt3 and ilt4-related compositons and methods |
| WO2003000199A2 (en) | 2001-06-25 | 2003-01-03 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
| AU2002339845B2 (en) | 2001-08-03 | 2009-03-26 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| MXPA04004491A (es) | 2001-11-14 | 2005-05-16 | Immunex Corp | Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
| US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| EP1678314B1 (en) | 2003-10-22 | 2012-09-05 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック， インコーポレイテッド | ヒト化抗ＴＧＦ−β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| EP1841874B1 (en) | 2005-01-27 | 2010-01-06 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| WO2006138739A2 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| JP2010509612A (ja) | 2006-11-14 | 2010-03-25 | ジェネンテック インコーポレイテッド | ニューロン再生の活性調節因子 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2676529C (en) | 2007-01-24 | 2014-03-25 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2009076359A2 (en) | 2007-12-11 | 2009-06-18 | Genentech, Inc. | Modulators of neuronal regeneration |
| AU2009246443A1 (en) | 2008-05-13 | 2009-11-19 | Genentech, Inc. | Anti-PirB antibodies |
| AR086287A1 (es) | 2011-05-05 | 2013-12-04 | Baylor Res Inst | Composicion inmunoestimulante, metodo |
| WO2013181438A2 (en) | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
| US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| US10138286B2 (en) | 2013-03-12 | 2018-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| EA028424B1 (ru) | 2013-03-15 | 2017-11-30 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| AU2015264120A1 (en) * | 2014-05-22 | 2016-11-24 | Board Of Regents Of The University Of Texas System | LILRB2 and notch-mediated expansion of hematopoietic precursor cells |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA2976130A1 (en) | 2015-02-11 | 2016-08-18 | University Health Network | Methods and compositions for modulating lilr proteins |
| CN107530402B (zh) * | 2015-03-06 | 2021-06-11 | 德克萨斯大学体系董事会 | 抗lilrb抗体及其在检测和治疗癌症中的用途 |
| BR112017020054A2 (pt) | 2015-03-23 | 2018-06-05 | Jounce Therapeutics Inc | anticorpos para icos |
| HUE057559T2 (hu) | 2016-11-02 | 2022-06-28 | Jounce Therapeutics Inc | PD-1 elleni antitestek és alkalmazásaik |
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| AU2018389111A1 (en) | 2017-12-22 | 2020-06-18 | Jounce Therapeutics, Inc. | Antibodies to LILRB2 |
| MX2021000009A (es) | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
-
2018
- 2018-12-20 AU AU2018389111A patent/AU2018389111A1/en active Pending
- 2018-12-20 JP JP2020554055A patent/JP7391868B2/ja active Active
- 2018-12-20 CN CN201880083004.7A patent/CN111699196A/zh active Pending
- 2018-12-20 BR BR112020012650-0A patent/BR112020012650A2/pt unknown
- 2018-12-20 EP EP18836765.0A patent/EP3728318A2/en active Pending
- 2018-12-20 EP EP22216659.7A patent/EP4219559A3/en active Pending
- 2018-12-20 EA EA202091540A patent/EA202091540A1/ru unknown
- 2018-12-20 MX MX2020006668A patent/MX2020006668A/es unknown
- 2018-12-20 US US16/228,084 patent/US10723798B2/en active Active
- 2018-12-20 KR KR1020207019622A patent/KR20200103706A/ko unknown
- 2018-12-20 WO PCT/US2018/066819 patent/WO2019126514A2/en unknown
- 2018-12-20 AR ARP180103767A patent/AR114002A1/es unknown
- 2018-12-20 CA CA3087166A patent/CA3087166A1/en active Pending
- 2018-12-20 SG SG11202004806SA patent/SG11202004806SA/en unknown
-
2020
- 2020-03-11 US US16/815,837 patent/US20200207856A1/en not_active Abandoned
- 2020-06-10 IL IL275268A patent/IL275268A/he unknown
- 2020-06-17 CL CL2020001637A patent/CL2020001637A1/es unknown
- 2020-07-14 US US16/928,663 patent/US11359019B2/en active Active
-
2022
- 2022-06-13 US US17/838,426 patent/US20230053631A1/en active Pending
-
2023
- 2023-11-22 JP JP2023197857A patent/JP2024026140A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024026140A (ja) | 2024-02-28 |
| JP7391868B2 (ja) | 2023-12-05 |
| US20230053631A1 (en) | 2023-02-23 |
| EA202091540A1 (ru) | 2021-03-22 |
| WO2019126514A2 (en) | 2019-06-27 |
| TW201930357A (zh) | 2019-08-01 |
| IL275268A (he) | 2020-07-30 |
| CA3087166A1 (en) | 2019-06-27 |
| EP3728318A2 (en) | 2020-10-28 |
| US20190194327A1 (en) | 2019-06-27 |
| EP4219559A3 (en) | 2023-10-18 |
| AU2018389111A1 (en) | 2020-06-18 |
| MX2020006668A (es) | 2020-10-07 |
| US10723798B2 (en) | 2020-07-28 |
| EP4219559A2 (en) | 2023-08-02 |
| CN111699196A (zh) | 2020-09-22 |
| KR20200103706A (ko) | 2020-09-02 |
| US11359019B2 (en) | 2022-06-14 |
| US20200339690A1 (en) | 2020-10-29 |
| JP2021506344A (ja) | 2021-02-22 |
| AR114002A1 (es) | 2020-07-08 |
| CL2020001637A1 (es) | 2021-02-19 |
| BR112020012650A2 (pt) | 2020-12-01 |
| WO2019126514A3 (en) | 2019-08-08 |
| US20200207856A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275268A (he) | נוגדנים כנגד lilrb2 | |
| IL285287A (he) | נוגדנים ל–tigit | |
| IL261188A (he) | נוגדנים כנגד tigit | |
| HK1253507A1 (zh) | 抗 ror1 抗體 | |
| HK1254836A1 (zh) | 抗-ror1抗體 | |
| HK1256116A1 (zh) | 抗lag-3抗體 | |
| GB201521391D0 (en) | Antibodies | |
| GB201521393D0 (en) | Antibodies | |
| IL253633A0 (he) | נוגדנים נגד טראנסתירטין | |
| HK1246804A1 (zh) | Tau結合抗體 | |
| GB201521382D0 (en) | Antibodies | |
| IL255323A0 (he) | נוגדנים אנטי-fcrn | |
| HK1255056A1 (zh) | 抗cd115抗體 | |
| PL3250593T3 (pl) | Przeciwciała przeciwko transtyretynie | |
| GB201609742D0 (en) | Improvements relating to antibodies | |
| GB201522394D0 (en) | Antibodies | |
| GB201503438D0 (en) | Antibodies | |
| IL284022A (he) | נוגדנים נגד טראנסתירטין | |
| GB201518728D0 (en) | Antibodies | |
| GB201515572D0 (en) | Anti-LAG-3 antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies | |
| GB201514425D0 (en) | Antibodies | |
| GB201508437D0 (en) | Antibodies | |
| GB201508444D0 (en) | Antibodies | |
| GB201507541D0 (en) | Antibodies |